JP2014507445A5 - - Google Patents

Download PDF

Info

Publication number
JP2014507445A5
JP2014507445A5 JP2013555599A JP2013555599A JP2014507445A5 JP 2014507445 A5 JP2014507445 A5 JP 2014507445A5 JP 2013555599 A JP2013555599 A JP 2013555599A JP 2013555599 A JP2013555599 A JP 2013555599A JP 2014507445 A5 JP2014507445 A5 JP 2014507445A5
Authority
JP
Japan
Prior art keywords
compound
alkyl
aryl
heteroaryl
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013555599A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014507445A (ja
JP6043733B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/026517 external-priority patent/WO2012116279A1/en
Publication of JP2014507445A publication Critical patent/JP2014507445A/ja
Publication of JP2014507445A5 publication Critical patent/JP2014507445A5/ja
Application granted granted Critical
Publication of JP6043733B2 publication Critical patent/JP6043733B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013555599A 2011-02-25 2012-02-24 カンナビノイド受容体モジュレーター Expired - Fee Related JP6043733B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161446729P 2011-02-25 2011-02-25
US61/446,729 2011-02-25
PCT/US2012/026517 WO2012116279A1 (en) 2011-02-25 2012-02-24 Cannabinoid receptor modulators

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016221615A Division JP2017039773A (ja) 2011-02-25 2016-11-14 カンナビノイド受容体モジュレーター

Publications (3)

Publication Number Publication Date
JP2014507445A JP2014507445A (ja) 2014-03-27
JP2014507445A5 true JP2014507445A5 (https=) 2015-04-09
JP6043733B2 JP6043733B2 (ja) 2016-12-14

Family

ID=46000314

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2013555599A Expired - Fee Related JP6043733B2 (ja) 2011-02-25 2012-02-24 カンナビノイド受容体モジュレーター
JP2016221615A Withdrawn JP2017039773A (ja) 2011-02-25 2016-11-14 カンナビノイド受容体モジュレーター
JP2018106019A Withdrawn JP2018162260A (ja) 2011-02-25 2018-06-01 カンナビノイド受容体モジュレーター
JP2020028389A Withdrawn JP2020079302A (ja) 2011-02-25 2020-02-21 カンナビノイド受容体モジュレーター
JP2022029449A Pending JP2022066289A (ja) 2011-02-25 2022-02-28 カンナビノイド受容体モジュレーター

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2016221615A Withdrawn JP2017039773A (ja) 2011-02-25 2016-11-14 カンナビノイド受容体モジュレーター
JP2018106019A Withdrawn JP2018162260A (ja) 2011-02-25 2018-06-01 カンナビノイド受容体モジュレーター
JP2020028389A Withdrawn JP2020079302A (ja) 2011-02-25 2020-02-21 カンナビノイド受容体モジュレーター
JP2022029449A Pending JP2022066289A (ja) 2011-02-25 2022-02-28 カンナビノイド受容体モジュレーター

Country Status (11)

Country Link
US (6) US20140206649A1 (https=)
EP (2) EP2678318A1 (https=)
JP (5) JP6043733B2 (https=)
CN (2) CN103492369B (https=)
AU (1) AU2012222149B2 (https=)
DK (1) DK3385252T3 (https=)
ES (1) ES2929977T3 (https=)
IL (2) IL227779A0 (https=)
MX (2) MX346644B (https=)
PT (1) PT3385252T (https=)
WO (1) WO2012116279A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2012DN02474A (https=) * 2009-08-28 2015-08-21 Arena Pharm Inc
US9597340B2 (en) 2011-02-25 2017-03-21 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
AU2012222149B2 (en) 2011-02-25 2017-06-29 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
EP2678330A1 (en) 2011-02-25 2014-01-01 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of condensed azacycles ( cannabinoid receptor modulators)
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
EP2845625A1 (en) * 2013-09-04 2015-03-11 Grünenthal GmbH Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
CA2955229C (en) 2014-07-17 2020-03-10 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
AU2017249211A1 (en) * 2016-04-10 2018-11-22 Arena Pharmaceuticals, Inc. Methods of treatment with selective CB2 receptor agonists
US20200078358A1 (en) 2017-05-08 2020-03-12 Arena Pharmaceuticals, Inc. Compounds and Methods for Treatment of Visceral Pain
WO2021047581A1 (zh) * 2019-09-12 2021-03-18 四川海思科制药有限公司 一种六氢化苯并吡唑衍生物及其制备
WO2021047583A1 (zh) * 2019-09-12 2021-03-18 四川海思科制药有限公司 一种三环吡唑衍生物及其制备
CN118843120A (zh) * 2020-09-07 2024-10-25 中兴通讯股份有限公司 资源确定方法、通信节点及存储介质
US20250127789A1 (en) 2021-11-04 2025-04-24 Skyhawk Therapeutics, Inc. Compositions useful for modulating splicing
WO2023212237A1 (en) 2022-04-27 2023-11-02 Skyhawk Therapeutics, Inc. Compositions useful for modulating splicing
US20260001889A1 (en) 2022-05-12 2026-01-01 Skyhawk Therapeutics, Inc. Compositions useful for modulating splicing

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US236010A (en) 1880-12-28 Wilhelm effer
US5605906A (en) 1995-03-24 1997-02-25 Merck Frosst Canada, Inc. Cannabinoid receptor agonists
JP3964478B2 (ja) 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
US7308894B2 (en) 1998-06-03 2007-12-18 Scott Laboratories, Inc. Apparatuses and methods for providing a conscious patient relief from pain and anxiety associated with medical or surgical procedures according to appropriate clinical heuristics
YU72201A (sh) 1999-04-28 2005-07-19 Aventis Pharma Deutschland Gmbh. Derivati di-aril kiseline kao ppar receptorski ligandi
EP1461027A4 (en) 2001-12-07 2005-09-07 Univ Virginia Commonwealth TREATMENT OF NEOPLASIA
IL150302A (en) 2002-01-31 2008-07-08 Naim Menashe Bicyclic cb2 cannabinoid receptor ligands
SE0300010D0 (sv) 2003-01-07 2003-01-07 Astrazeneca Ab Novel Compounds
WO2005123677A1 (en) 2004-06-16 2005-12-29 Actelion Pharmaceuticals Ltd 4-carbonyl substituted 1,1,2-trimethyl-1a,4,5,5a-tetrahydro-1h-4-aza-cyclopropa'a!pentalene derivatives as agonists for the g-protein-coupled receptor s1p1/edg1 and immunosuppressive agents
EP2343302A1 (en) 2004-07-12 2011-07-13 Cadila Healthcare Limited Tricyclic pyrazole derivatives as cannabinoid receptor modulators
FR2875230A1 (fr) * 2004-09-13 2006-03-17 Sanofi Aventis Sa Derives de pyrazole condense, leur preparation et leur application en therapeutique
DE102004054666A1 (de) 2004-11-12 2006-05-18 Bayer Cropscience Gmbh Substituierte Pyrazol-3-carboxamide, Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
PE20060949A1 (es) * 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
CA2613678A1 (en) * 2005-06-02 2006-12-07 Glenmark Pharmaceuticals S.A. Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
US7597910B2 (en) 2005-08-20 2009-10-06 Slgm Medical Research Institute Compositions and methods for treating prostate disorders
BRPI0616263A2 (pt) * 2005-09-23 2011-06-14 Janssen Pharmaceutica Nv moduladores canabinàides do tipo tetrahidro-ciclopentil pirazol
ATE459352T1 (de) 2006-07-04 2010-03-15 Janssen Pharmaceutica Nv Benzimidazol-cannabinoid-agonisten mit einer substituierten heterocyclischen gruppe
US7928123B2 (en) 2006-09-25 2011-04-19 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
US8481574B2 (en) 2006-10-12 2013-07-09 Abbott Laboratories Compounds as cannabinoid receptor ligands
WO2008048914A1 (en) 2006-10-17 2008-04-24 Boehringer Ingelheim International Gmbh Polycyclic compounds which modulate the cb2 receptor
EP2091921A2 (en) 2006-11-03 2009-08-26 Glenmark Pharmaceuticals S.A. Bridged bicyclic indazoles as cannabinoid receptor ligands
US8173638B2 (en) 2006-11-21 2012-05-08 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
US9763894B2 (en) 2006-12-05 2017-09-19 Virginia Commonwealth University Inflammation therapy
US20080161340A1 (en) 2006-12-20 2008-07-03 Cara Therapeutics, Inc. Tetrahydroquinilinones, tetrahydronaphthyridones and derivatives thereof
WO2008085302A1 (en) 2006-12-20 2008-07-17 Merck & Co., Inc. Imidazopyridine analogs as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases
US20080214537A1 (en) 2007-03-02 2008-09-04 Cara Therapeutics, Inc. Bridged phenanthridines
US8193369B2 (en) 2007-03-30 2012-06-05 Janssen Pharmaceutica Nv Benzimidazole cannabinoid agonists
WO2008157500A1 (en) 2007-06-17 2008-12-24 Kalypsys, Inc. Aminoquinazoline cannabinoid receptor modulators for treatment of disease
CN101686989B (zh) 2007-06-21 2016-10-19 卡拉治疗学股份有限公司 取代的咪唑并杂环
US8338623B2 (en) 2007-07-09 2012-12-25 Abbvie Inc. Compounds as cannabinoid receptor ligands
US7943658B2 (en) 2007-07-23 2011-05-17 Bristol-Myers Squibb Company Indole indane amide compounds useful as CB2 agonists and method
EP2203171A2 (en) 2007-08-21 2010-07-07 Merck Sharp & Dohme Corp. Cb2 receptor ligands for the treatment of pain
UA104010C2 (en) 2008-12-18 2013-12-25 Эли Лилли Энд Компани Purine compounds
US7741350B1 (en) 2009-01-28 2010-06-22 Cara Therapeutics, Inc. Bicyclic pyrazolo-heterocycles
WO2010088050A2 (en) * 2009-01-28 2010-08-05 Cara Therapeutics, Inc. Bicyclic pyrazolo-heterocycles
IN2012DN02474A (https=) * 2009-08-28 2015-08-21 Arena Pharm Inc
US9597340B2 (en) 2011-02-25 2017-03-21 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
WO2012116278A1 (en) 2011-02-25 2012-08-30 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
AU2012222149B2 (en) 2011-02-25 2017-06-29 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
EP2678330A1 (en) * 2011-02-25 2014-01-01 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of condensed azacycles ( cannabinoid receptor modulators)

Similar Documents

Publication Publication Date Title
JP2014507445A5 (https=)
US8529947B2 (en) Alkaloid formulations
KR101677126B1 (ko) 탄산염 프로드러그 및 그것의 사용 방법
JP5598775B2 (ja) 癌の介入治療および根絶のためのｉｔｅとその類似体を含む医薬組成物
JP2011520977A5 (https=)
WO2008131056A3 (en) Sustained release monoeximic formulations of opioid and nonopioid analgesics
MY180666A (en) Substituted pyrazolo [3,4-b] pyridines as medicaments
CA2544648C (en) Analgesic compounds, their synthesis and pharmaceutical compositions containing them
JP2018162260A (ja) カンナビノイド受容体モジュレーター
JP2018520195A5 (https=)
WO2008131057A3 (en) Sustained release formulations of opioid and nonopioid analgesics
CN103619330A (zh) 用于治疗糖尿病的选择性雄激素受体调节剂
MA33922B1 (fr) Dérivés hétéroaromatiques de phénylimidazole en tant qu'inhibiteurs de l'enzyme pde10a
JP2016516773A5 (https=)
US20150065526A1 (en) Overcoming acquired resistance to chemotherapy treatments through suppression of stat3
EP2714043A1 (en) Compositions for sequential administration of opioid receptor agonists
JP2012516288A (ja) 薬物乱用抑制剤、方法および組成物
US8598221B2 (en) Synergistic combination of analgesic compounds
CN109758452A (zh) 胺类化合物治疗疼痛的医药用途
RU2010140888A (ru) Улучшенные противораковые терапии
DK2091520T3 (da) Oral doseringsform omfattende trisubstituerede glycerol-forbindelser
JP2011502985A5 (https=)
JP2013227347A5 (https=)
US9592226B2 (en) Solenopsin and derivatives, therapeutic compositions; and methods related thereto
CZ2006623A3 (cs) Kombinace deramciklanu a opioidů jako analgetik